0 results available. Select is focused ,type to refine list, press Down to open the menu,
Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The compan...
The following section summarizes insights on Inozyme Pharma Inc's Revenue CAGR (5y):
To view the full list of supported financial metrics please see Complete Metrics Listing.
Metrics similar to Revenue CAGR (5y) in the growth category include:
Five-year compound annual growth rate in revenue.
Revenue CAGR (5y) measures the five-year compound annual growth rate in Revenue.
Compound annual growth rate (CAGR) is a commonly used business and investing term that measures the growth of a metric over multiple periods. CAGRs are useful since they reduce the effect of volatility in specific periods, unlike arithmetic means.
Growth calculations are always made in the company’s reporting currency to ensure currency fluctuations do not impact the calculation. Inozyme Pharma’s reports in the USD currency. You can read more about Revenue here and compound annual growth rate on Wikipedia. You may also find variants three-year Revenue CAGR, and seven-year Revenue CAGR useful.
The chart above depicts the distribution of revenue cagr (5y) for companies operating in the Healthcare sector in the Developed economic region. Over 1,520 companies were considered in this analysis, and 1,463 had meaningful values. The average revenue cagr (5y) of companies in the sector is 16.3% with a standard deviation of 30.5%.
Inozyme Pharma Inc's Revenue CAGR (5y) of NM- ranks in the - percentile for the sector. The following table provides additional summary stats:
| Economic Risk Region | Developed |
| Total Constituents | 1,522 |
| Included Constituents | 1,463 |
| Min | -45.9% |
| Max | 178.0% |
| Median | 9.4% |
| Mean | 16.3% |
| Standard Deviation | 30.5% |
You can find companies with similar revenue cagr (5y) using this stock screener.